Study of CAD-9303 in Subjects With Schizophrenia
Completed · Phase 1 · Has a placebo group
Conditions studied: Schizophrenia
In brief
This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in participants with schizophrenia.
Key facts
- Study ID
- NCT04306146
- Run by
- Cadent Therapeutics
- People needed
- 103
- Starts
- 2020-02-28
- Expected to finish
- 2021-11-24
- Last updated by the study team
- 2021-12-15
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Collaborative Neuroscience Research — Long Beach, California, United States
- Hassman Research Institute — Marlton, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.